Roivant Sciences Ltd. (ROIV) Stock Competitors & Peer Comparison
See (ROIV) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ROIV | $32.21 | +3.07% | 23.2B | -59.65 | -$0.54 | N/A |
| VRTX | $468.42 | +0.35% | 118.9B | 27.79 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $618.03 | +0.90% | 63.7B | 15.08 | $40.99 | +0.59% |
| ARGX | $853.40 | -5.57% | 52.8B | 37.98 | $22.47 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $288.18 | +0.62% | 38.5B | 72.41 | $3.98 | N/A |
| RVMDW | $7.41 | +4.07% | 37.2B | N/A | N/A | N/A |
| RVMD | $169.51 | +2.23% | 36B | -23.84 | -$7.11 | N/A |
| MRNA | $61.00 | +2.79% | 24.2B | -7.49 | -$8.14 | N/A |
Stock Comparison
ROIV vs VRTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, VRTX has a market cap of 118.9B. Regarding current trading prices, ROIV is priced at $32.21, while VRTX trades at $468.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas VRTX's P/E ratio is 27.79. In terms of profitability, ROIV's ROE is -0.07%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ROIV is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check VRTX's competition here
ROIV vs VRNA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ROIV is priced at $32.21, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ROIV's ROE is -0.07%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ROIV is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check VRNA's competition here
ROIV vs REGN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, REGN has a market cap of 63.7B. Regarding current trading prices, ROIV is priced at $32.21, while REGN trades at $618.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas REGN's P/E ratio is 15.08. In terms of profitability, ROIV's ROE is -0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ROIV is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check REGN's competition here
ROIV vs ARGX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ARGX has a market cap of 52.8B. Regarding current trading prices, ROIV is priced at $32.21, while ARGX trades at $853.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ARGX's P/E ratio is 37.98. In terms of profitability, ROIV's ROE is -0.07%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, ROIV is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ARGX's competition here
ROIV vs SGEN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ROIV is priced at $32.21, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ROIV's ROE is -0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ROIV is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check SGEN's competition here
ROIV vs ALNY Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ALNY has a market cap of 38.5B. Regarding current trading prices, ROIV is priced at $32.21, while ALNY trades at $288.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ALNY's P/E ratio is 72.41. In terms of profitability, ROIV's ROE is -0.07%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ROIV is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ALNY's competition here
ROIV vs RVMDW Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RVMDW has a market cap of 37.2B. Regarding current trading prices, ROIV is priced at $32.21, while RVMDW trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RVMDW's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ROIV is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check RVMDW's competition here
ROIV vs RVMD Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RVMD has a market cap of 36B. Regarding current trading prices, ROIV is priced at $32.21, while RVMD trades at $169.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RVMD's P/E ratio is -23.84. In terms of profitability, ROIV's ROE is -0.07%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ROIV is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RVMD's competition here
ROIV vs MRNA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MRNA has a market cap of 24.2B. Regarding current trading prices, ROIV is priced at $32.21, while MRNA trades at $61.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MRNA's P/E ratio is -7.49. In terms of profitability, ROIV's ROE is -0.07%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ROIV is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check MRNA's competition here
ROIV vs RPRX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RPRX has a market cap of 23.8B. Regarding current trading prices, ROIV is priced at $32.21, while RPRX trades at $55.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RPRX's P/E ratio is 29.13. In terms of profitability, ROIV's ROE is -0.07%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ROIV is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RPRX's competition here
ROIV vs UTHR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, ROIV is priced at $32.21, while UTHR trades at $544.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas UTHR's P/E ratio is 20.13. In terms of profitability, ROIV's ROE is -0.07%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ROIV is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check UTHR's competition here
ROIV vs BNTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ROIV is priced at $32.21, while BNTX trades at $90.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas BNTX's P/E ratio is -15.57. In terms of profitability, ROIV's ROE is -0.07%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ROIV is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BNTX's competition here
ROIV vs INSM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, INSM has a market cap of 22.1B. Regarding current trading prices, ROIV is priced at $32.21, while INSM trades at $102.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas INSM's P/E ratio is -17.73. In terms of profitability, ROIV's ROE is -0.07%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ROIV is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check INSM's competition here
ROIV vs INCY Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, INCY has a market cap of 20.9B. Regarding current trading prices, ROIV is priced at $32.21, while INCY trades at $104.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas INCY's P/E ratio is 14.03. In terms of profitability, ROIV's ROE is -0.07%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ROIV is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check INCY's competition here
ROIV vs BGNE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ROIV is priced at $32.21, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ROIV's ROE is -0.07%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ROIV is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BGNE's competition here
ROIV vs DNA-WT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ROIV is priced at $32.21, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ROIV is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check DNA-WT's competition here
ROIV vs NBIX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, ROIV is priced at $32.21, while NBIX trades at $161.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas NBIX's P/E ratio is 24.88. In terms of profitability, ROIV's ROE is -0.07%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ROIV is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check NBIX's competition here
ROIV vs GMAB Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, GMAB has a market cap of 15.9B. Regarding current trading prices, ROIV is priced at $32.21, while GMAB trades at $25.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas GMAB's P/E ratio is 19.80. In terms of profitability, ROIV's ROE is -0.07%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ROIV is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check GMAB's competition here
ROIV vs ASND Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, ROIV is priced at $32.21, while ASND trades at $238.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ASND's P/E ratio is 27.14. In terms of profitability, ROIV's ROE is -0.07%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ROIV is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ASND's competition here
ROIV vs JAZZ Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, ROIV is priced at $32.21, while JAZZ trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas JAZZ's P/E ratio is 2093.18. In terms of profitability, ROIV's ROE is -0.07%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ROIV is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check JAZZ's competition here
ROIV vs BBIO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, ROIV is priced at $32.21, while BBIO trades at $68.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas BBIO's P/E ratio is -18.35. In terms of profitability, ROIV's ROE is -0.07%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ROIV is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BBIO's competition here
ROIV vs EXEL Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, ROIV is priced at $32.21, while EXEL trades at $51.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas EXEL's P/E ratio is 17.00. In terms of profitability, ROIV's ROE is -0.07%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ROIV is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check EXEL's competition here
ROIV vs KRTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ROIV is priced at $32.21, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ROIV's ROE is -0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ROIV is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check KRTX's competition here
ROIV vs IONS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, IONS has a market cap of 12.6B. Regarding current trading prices, ROIV is priced at $32.21, while IONS trades at $75.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas IONS's P/E ratio is -37.81. In terms of profitability, ROIV's ROE is -0.07%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ROIV is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check IONS's competition here
ROIV vs AXSM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, AXSM has a market cap of 12.5B. Regarding current trading prices, ROIV is priced at $32.21, while AXSM trades at $241.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas AXSM's P/E ratio is -64.87. In terms of profitability, ROIV's ROE is -0.07%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ROIV is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check AXSM's competition here
ROIV vs MDGL Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, ROIV is priced at $32.21, while MDGL trades at $513.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MDGL's P/E ratio is -38.03. In terms of profitability, ROIV's ROE is -0.07%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ROIV is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MDGL's competition here
ROIV vs RNAM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ROIV is priced at $32.21, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ROIV's ROE is -0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ROIV is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RNAM's competition here
ROIV vs ARWR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ARWR has a market cap of 11.3B. Regarding current trading prices, ROIV is priced at $32.21, while ARWR trades at $79.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ARWR's P/E ratio is -35.20. In terms of profitability, ROIV's ROE is -0.07%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ROIV is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ARWR's competition here
ROIV vs SMMT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, ROIV is priced at $32.21, while SMMT trades at $14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas SMMT's P/E ratio is -8.96. In terms of profitability, ROIV's ROE is -0.07%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ROIV is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check SMMT's competition here
ROIV vs BMRN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, ROIV is priced at $32.21, while BMRN trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas BMRN's P/E ratio is 40.65. In terms of profitability, ROIV's ROE is -0.07%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ROIV is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BMRN's competition here
ROIV vs KRYS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, ROIV is priced at $32.21, while KRYS trades at $340.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas KRYS's P/E ratio is 45.48. In terms of profitability, ROIV's ROE is -0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ROIV is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check KRYS's competition here
ROIV vs CYTK Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, ROIV is priced at $32.21, while CYTK trades at $80.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CYTK's P/E ratio is -11.66. In terms of profitability, ROIV's ROE is -0.07%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ROIV is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CYTK's competition here
ROIV vs RXDX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ROIV is priced at $32.21, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ROIV's ROE is -0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ROIV is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RXDX's competition here
ROIV vs NUVL Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ROIV is priced at $32.21, while NUVL trades at $123.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas NUVL's P/E ratio is -20.37. In terms of profitability, ROIV's ROE is -0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ROIV is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check NUVL's competition here
ROIV vs TECH Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, TECH has a market cap of 8.8B. Regarding current trading prices, ROIV is priced at $32.21, while TECH trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas TECH's P/E ratio is 80.37. In terms of profitability, ROIV's ROE is -0.07%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ROIV is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check TECH's competition here
ROIV vs IMGN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ROIV is priced at $32.21, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ROIV's ROE is -0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ROIV is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check IMGN's competition here
ROIV vs CORT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CORT has a market cap of 8.6B. Regarding current trading prices, ROIV is priced at $32.21, while CORT trades at $79.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CORT's P/E ratio is 228.14. In terms of profitability, ROIV's ROE is -0.07%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ROIV is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CORT's competition here
ROIV vs BPMC Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ROIV is priced at $32.21, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ROIV's ROE is -0.07%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ROIV is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BPMC's competition here
ROIV vs HALO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, ROIV is priced at $32.21, while HALO trades at $69.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas HALO's P/E ratio is 24.43. In terms of profitability, ROIV's ROE is -0.07%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ROIV is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check HALO's competition here
ROIV vs TGTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, ROIV is priced at $32.21, while TGTX trades at $53.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas TGTX's P/E ratio is 18.54. In terms of profitability, ROIV's ROE is -0.07%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ROIV is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check TGTX's competition here
ROIV vs APGE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, ROIV is priced at $32.21, while APGE trades at $132.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas APGE's P/E ratio is -30.69. In terms of profitability, ROIV's ROE is -0.07%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ROIV is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check APGE's competition here
ROIV vs CERE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ROIV is priced at $32.21, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CERE's P/E ratio is -16.47. In terms of profitability, ROIV's ROE is -0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ROIV is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CERE's competition here
ROIV vs KYMR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, KYMR has a market cap of 8.1B. Regarding current trading prices, ROIV is priced at $32.21, while KYMR trades at $98.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas KYMR's P/E ratio is -27.44. In terms of profitability, ROIV's ROE is -0.07%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ROIV is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check KYMR's competition here
ROIV vs ALKS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, ROIV is priced at $32.21, while ALKS trades at $48.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ALKS's P/E ratio is 53.41. In terms of profitability, ROIV's ROE is -0.07%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ROIV is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ALKS's competition here
ROIV vs IMVT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, ROIV is priced at $32.21, while IMVT trades at $37.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas IMVT's P/E ratio is -13.58. In terms of profitability, ROIV's ROE is -0.07%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ROIV is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check IMVT's competition here
ROIV vs IBRX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, IBRX has a market cap of 7.7B. Regarding current trading prices, ROIV is priced at $32.21, while IBRX trades at $7.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas IBRX's P/E ratio is -8.61. In terms of profitability, ROIV's ROE is -0.07%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ROIV is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check IBRX's competition here
ROIV vs PTGX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, PTGX has a market cap of 7.7B. Regarding current trading prices, ROIV is priced at $32.21, while PTGX trades at $118.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas PTGX's P/E ratio is -65.72. In terms of profitability, ROIV's ROE is -0.07%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ROIV is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check PTGX's competition here
ROIV vs PCVX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, PCVX has a market cap of 7.5B. Regarding current trading prices, ROIV is priced at $32.21, while PCVX trades at $51.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas PCVX's P/E ratio is -7.54. In terms of profitability, ROIV's ROE is -0.07%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ROIV is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check PCVX's competition here
ROIV vs MTSR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ROIV is priced at $32.21, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ROIV's ROE is -0.07%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ROIV is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MTSR's competition here
ROIV vs RYTM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, ROIV is priced at $32.21, while RYTM trades at $106.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RYTM's P/E ratio is -33.93. In terms of profitability, ROIV's ROE is -0.07%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ROIV is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check RYTM's competition here
ROIV vs MRUS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ROIV is priced at $32.21, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ROIV's ROE is -0.07%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ROIV is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MRUS's competition here
ROIV vs PTCT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, PTCT has a market cap of 6.8B. Regarding current trading prices, ROIV is priced at $32.21, while PTCT trades at $82.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas PTCT's P/E ratio is -32.33. In terms of profitability, ROIV's ROE is -0.07%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ROIV is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check PTCT's competition here
ROIV vs ACLX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ROIV is priced at $32.21, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ROIV's ROE is -0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ROIV is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ACLX's competition here
ROIV vs LQDA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, LQDA has a market cap of 6.6B. Regarding current trading prices, ROIV is priced at $32.21, while LQDA trades at $74.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas LQDA's P/E ratio is 435.35. In terms of profitability, ROIV's ROE is -0.07%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ROIV is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check LQDA's competition here
ROIV vs RETA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ROIV is priced at $32.21, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RETA's P/E ratio is -66.29. In terms of profitability, ROIV's ROE is -0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ROIV is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RETA's competition here
ROIV vs PRAX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, PRAX has a market cap of 6.5B. Regarding current trading prices, ROIV is priced at $32.21, while PRAX trades at $305.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas PRAX's P/E ratio is -22.77. In terms of profitability, ROIV's ROE is -0.07%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ROIV is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check PRAX's competition here
ROIV vs ABVX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, ROIV is priced at $32.21, while ABVX trades at $98.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ABVX's P/E ratio is -18.40. In terms of profitability, ROIV's ROE is -0.07%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ROIV is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ABVX's competition here
ROIV vs CNTA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ROIV is priced at $32.21, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ROIV's ROE is -0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ROIV is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CNTA's competition here
ROIV vs COGT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, ROIV is priced at $32.21, while COGT trades at $36.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas COGT's P/E ratio is -16.73. In terms of profitability, ROIV's ROE is -0.07%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ROIV is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check COGT's competition here
ROIV vs SRRK Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, SRRK has a market cap of 6.1B. Regarding current trading prices, ROIV is priced at $32.21, while SRRK trades at $51.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas SRRK's P/E ratio is -14.82. In terms of profitability, ROIV's ROE is -0.07%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ROIV is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check SRRK's competition here
ROIV vs SYRE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, SYRE has a market cap of 5.9B. Regarding current trading prices, ROIV is priced at $32.21, while SYRE trades at $97.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas SYRE's P/E ratio is -45.78. In terms of profitability, ROIV's ROE is -0.07%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ROIV is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check SYRE's competition here
ROIV vs BLTE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, BLTE has a market cap of 5.8B. Regarding current trading prices, ROIV is priced at $32.21, while BLTE trades at $145.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas BLTE's P/E ratio is -57.12. In terms of profitability, ROIV's ROE is -0.07%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ROIV is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BLTE's competition here
ROIV vs CGON Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CGON has a market cap of 5.8B. Regarding current trading prices, ROIV is priced at $32.21, while CGON trades at $65.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CGON's P/E ratio is -28.09. In terms of profitability, ROIV's ROE is -0.07%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ROIV is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CGON's competition here
ROIV vs CDTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ROIV is priced at $32.21, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ROIV's ROE is -0.07%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ROIV is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CDTX's competition here
ROIV vs LGND Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, ROIV is priced at $32.21, while LGND trades at $279.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas LGND's P/E ratio is 36.29. In terms of profitability, ROIV's ROE is -0.07%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ROIV is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check LGND's competition here
ROIV vs MIRM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, ROIV is priced at $32.21, while MIRM trades at $111.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MIRM's P/E ratio is -8.15. In terms of profitability, ROIV's ROE is -0.07%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ROIV is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MIRM's competition here
ROIV vs ABCM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ROIV is priced at $32.21, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ROIV's ROE is -0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ROIV is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ABCM's competition here
ROIV vs ISEE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ROIV is priced at $32.21, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ROIV's ROE is -0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ROIV is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ISEE's competition here
ROIV vs LEGN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, ROIV is priced at $32.21, while LEGN trades at $29.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas LEGN's P/E ratio is -21.23. In terms of profitability, ROIV's ROE is -0.07%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ROIV is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check LEGN's competition here
ROIV vs FBIOX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, ROIV is priced at $32.21, while FBIOX trades at $26.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to FBIOX's ROE of N/A. Regarding short-term risk, ROIV is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check FBIOX's competition here
ROIV vs APLS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ROIV is priced at $32.21, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas APLS's P/E ratio is 38.35. In terms of profitability, ROIV's ROE is -0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ROIV is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check APLS's competition here
ROIV vs CRSP Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ROIV is priced at $32.21, while CRSP trades at $53.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CRSP's P/E ratio is -8.75. In terms of profitability, ROIV's ROE is -0.07%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ROIV is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CRSP's competition here
ROIV vs TVTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ROIV is priced at $32.21, while TVTX trades at $55.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas TVTX's P/E ratio is -111.90. In terms of profitability, ROIV's ROE is -0.07%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ROIV is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check TVTX's competition here
ROIV vs CAI Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CAI has a market cap of 5B. Regarding current trading prices, ROIV is priced at $32.21, while CAI trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CAI's P/E ratio is -6.37. In terms of profitability, ROIV's ROE is -0.07%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ROIV is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CAI's competition here
ROIV vs TERN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ROIV is priced at $32.21, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas TERN's P/E ratio is -51.41. In terms of profitability, ROIV's ROE is -0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ROIV is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check TERN's competition here
ROIV vs ERAS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, ROIV is priced at $32.21, while ERAS trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ERAS's P/E ratio is -16.20. In terms of profitability, ROIV's ROE is -0.07%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ROIV is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ERAS's competition here
ROIV vs FOLD Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $32.21, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ROIV's ROE is -0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ROIV is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check FOLD's competition here
ROIV vs AKRO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $32.21, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ROIV's ROE is -0.07%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ROIV is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check AKRO's competition here
ROIV vs KNSA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, KNSA has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $32.21, while KNSA trades at $59.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas KNSA's P/E ratio is 65.37. In terms of profitability, ROIV's ROE is -0.07%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ROIV is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check KNSA's competition here
ROIV vs ALPN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $32.21, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ROIV's ROE is -0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ROIV is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ALPN's competition here
ROIV vs CELC Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, ROIV is priced at $32.21, while CELC trades at $90.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CELC's P/E ratio is -23.13. In terms of profitability, ROIV's ROE is -0.07%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ROIV is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CELC's competition here
ROIV vs MANE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, ROIV is priced at $32.21, while MANE trades at $103.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MANE's P/E ratio is -39.08. In terms of profitability, ROIV's ROE is -0.07%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ROIV is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MANE's competition here
ROIV vs XENE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, ROIV is priced at $32.21, while XENE trades at $54.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas XENE's P/E ratio is -11.62. In terms of profitability, ROIV's ROE is -0.07%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ROIV is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check XENE's competition here
ROIV vs VCYT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, VCYT has a market cap of 4.3B. Regarding current trading prices, ROIV is priced at $32.21, while VCYT trades at $53.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas VCYT's P/E ratio is 49.81. In terms of profitability, ROIV's ROE is -0.07%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ROIV is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check VCYT's competition here
ROIV vs OPT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ROIV is priced at $32.21, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas OPT's P/E ratio is -1.52. In terms of profitability, ROIV's ROE is -0.07%, compared to OPT's ROE of +1.09%. Regarding short-term risk, ROIV is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check OPT's competition here
ROIV vs EWTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, ROIV is priced at $32.21, while EWTX trades at $38.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas EWTX's P/E ratio is -23.39. In terms of profitability, ROIV's ROE is -0.07%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ROIV is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check EWTX's competition here
ROIV vs MRTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ROIV is priced at $32.21, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ROIV's ROE is -0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ROIV is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MRTX's competition here
ROIV vs VKTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ROIV is priced at $32.21, while VKTX trades at $34.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas VKTX's P/E ratio is -8.39. In terms of profitability, ROIV's ROE is -0.07%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ROIV is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check VKTX's competition here
ROIV vs DFTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, DFTX has a market cap of 3.9B. Regarding current trading prices, ROIV is priced at $32.21, while DFTX trades at $36.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas DFTX's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ROIV is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check DFTX's competition here
ROIV vs DNLI Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, ROIV is priced at $32.21, while DNLI trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas DNLI's P/E ratio is -8.60. In terms of profitability, ROIV's ROE is -0.07%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ROIV is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check DNLI's competition here
ROIV vs ACAD Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, ROIV is priced at $32.21, while ACAD trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas ACAD's P/E ratio is 10.23. In terms of profitability, ROIV's ROE is -0.07%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ROIV is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ACAD's competition here
ROIV vs CPRX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ROIV is priced at $32.21, while CPRX trades at $31.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CPRX's P/E ratio is 18.15. In terms of profitability, ROIV's ROE is -0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ROIV is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CPRX's competition here
ROIV vs CRNX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, ROIV is priced at $32.21, while CRNX trades at $35.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CRNX's P/E ratio is -6.99. In terms of profitability, ROIV's ROE is -0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ROIV is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CRNX's competition here
ROIV vs RYZB Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ROIV is priced at $32.21, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ROIV's ROE is -0.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ROIV is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RYZB's competition here
ROIV vs CBAY Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $32.21, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ROIV's ROE is -0.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ROIV is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CBAY's competition here
ROIV vs NAMS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $32.21, while NAMS trades at $31.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas NAMS's P/E ratio is -17.64. In terms of profitability, ROIV's ROE is -0.07%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ROIV is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check NAMS's competition here
ROIV vs DNTH Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $32.21, while DNTH trades at $87.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas DNTH's P/E ratio is -20.69. In terms of profitability, ROIV's ROE is -0.07%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ROIV is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check DNTH's competition here
ROIV vs NAMSW Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, ROIV is priced at $32.21, while NAMSW trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas NAMSW's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ROIV is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check NAMSW's competition here
ROIV vs SWTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 23.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ROIV is priced at $32.21, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -59.65, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ROIV's ROE is -0.07%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ROIV is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check SWTX's competition here